ClinicalTrials.gg
RecruitingNCT05645068OCTACTIPHUpdated May 15, 2023

Retinal Microvasculature by Optical Coherence Tomography Angiography During Integrating Physical Activity in Diabetic Subjects.

An interventional study of Optical Coherence Tomography Angiography and multidisciplinary care program in Diabetes Complications, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Complications with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Complications · France.

Started
2023
with 2 others
No phase
6 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
University Hospital, Toulouse

Among the 11 studies in Diabetes Complications with a site in France, this one is one of 3 that started in 2023, is one of 6 with no phase, and was the 9th registered.

Diabetes Complications

267 studies on the registry are indexed under Diabetes Complications; 54 are open to participants now.

Browse Diabetes Complications studies →

Open to participants now

3 of the 11 studies in Diabetes Complications with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 45 Diabetes Complications studies recruiting now, 27 (60%) set no upper age limit and 12 (27%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Complications with a site in France, or all of them as a file.
02

Study summary

Diabetic retinopathy is a common condition of diabetes and can lead to blindness, making it one of the most feared complications of diabetes.

Recently, it has been proven that the parameters measured by Optical Coherence Tomography (OCT) Angiography: the vascular density of the macular retinal capillary plexi and the foveolar avascular zone, can be modified after a high-intensity sports training program in healthy subjects.

the team wants to study the evolution of the macular, in type 2 diabetic subjects, before and after a stay in a care structure dedicated to the multidisciplinary and integrative management (nutrition, physical activity, therapeutic education) of a duration of 3 weeks.

Read the detailed description

The prevention of vascular and neurological complications in diabetic subjects represents a major public health issue. Diabetic retinopathy is a common condition of diabetes and can lead to blindness, making it one of the most feared complications of diabetes.

Diabetes management is global and aims at a stable glycemic balance putting the patient out of the micro and macrovascular complications linked to this pathology. It involves modifying the lifestyle of patients with the practice of appropriate physical activity, balancing daily food intake, not necessarily by taking insulin-sensitizing or hypoglycemic drug treatment, but also by management of other risk factors related to complications: dyslipidemia, weight, smoking, arterial blood pressure balance.

The use of Optical Coherence Tomography Angiography allow the evaluation of the microvasculature of the macula.

Diabetic macular edema is the leading cause of vision loss in type 2 diabetic subjects mainly due to dysfunction of the macular microvasculature.

Macular analysis via Optical Coherence Tomography Angiography can quickly and non-invasively predict the risk of occurrence of Diabetic macular edema and therefore that of a decrease in acuity and visual impairment.

03

Conditions studied

  • Diabetes Complications

Keywords

  • Optical Coherence Tomography Angiography
  • Diabetic Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient for whom a 3-week multidisciplinary and integrative program was offered in a diabetology unit
  • Patient having given his consent
  • Patient affiliated to a social security scheme or equivalent
  • Patient with type 2 diabetes

Exclusion criteria

Exclusion Criteria:

  • History of exudative or tractional retinal detachment
  • Intraocular foreign body
  • History of endophthalmitis
  • History of inflammatory disease of the retina
  • History of chorioretinitis
  • Patient with age-related macular degeneration
  • Patients with type 1 diabetes or secondary diabetes
  • Uncontrolled hypertension does not define Systolic arterial pressure (SAP) > 180 mmHg or Diastolic arterial pressure (DAP) > 110 mmHg
  • Patient who has already received intravitreal injections of anti-angiogenic molecules.
  • Pregnant or breastfeeding patient at the time of the study
  • Persons under a legal protection regime for adults (safeguard of justice, guardianship, curatorship, institutionalized, or under mandate for future protection)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Optical Coherence Tomography Angiography

    Diagnostic Test: Optical Coherence Tomography Angiography · Other: multidisciplinary care program

Interventions

  • Diagnostic testOptical Coherence Tomography Angiography

    Optical Coherence Tomography Angiography

  • Othermultidisciplinary care program

    multidisciplinary care program including sports activity

06

What researchers measure

Primary outcomes

  1. coefficient of variation of the superficial retinal capillary plexus

    coefficient of variation of the superficial retinal capillary plexus between day 0 and week 3 determinate by OCT Angiography

    Time frame: week 3

07

Study locations

1 of 1 sites recruiting
  • CHU de Toulouse
    Toulouse, 31400, France
    Recruiting
    • Fanny VARENNE, PH · Contact
    • Raphaël ADAM · Contact
    • Fanny VARENNE, PH · Principal investigator
    • Emilie LOBINET, PH · Principal investigator
    • Juliette SPIESS, PH · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2024, 13 months after the start.

Of 62 non-industry interventional studies with no phase under Diabetes Complications, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 13 months is below that.

Counting every sponsor, half of 69 studies reached it within 28 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Feb 28, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05645068
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Feb 28, 2023
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
May 15, 2023

Study contacts

Fanny VARENNE, PH
Contact
varenne.f@chu-toulouse.fr
05 61 77 11 07 ext. +33
Fanny VARENNE, PH
principal investigator · Toulouse University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion